Biosimilars: Nearly The End Already, Or Is The Best Yet To Come?
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Europe's first round of biosimilars have been poor, prompting some to suggest they're dead before they really got started. Others claim biosimilars' true value will come with the next wave: biosimilar antibodies.
You may also be interested in...
Biosimilars Uptake In EU Could Slow If Innovators Switch Pricing Strategy
Austerity has driven biosimilars in Europe, but IMS strategist cautions that further saving could be mercurial because of ancillary costs.
Biosimilars Development In EU Could Get Easier; EC Mulls Accepting Outside Data
Industry applauds a suggestion by a senior healthcare representative that the European Commission could re-examine the overarching guideline on biosimilars to promote global development, but growth ultimately will be determined by greater worldwide harmonization.
Biosimilars: A New Kind Of Innovation
The lesson from first-generation biosimilars is that these aren't just small-molecule style copies. They require significant clinical and commercial support to overcome prescriber skepticism. For those lining up to tap into the next-generation opportunity, biosimilars represent a new kind of innovation, where the novelty lies in a drug's value-focused pricing, quality, cost-effective production, and in peripherals such as support-services and means of delivery. Although biosimilar market dynamics will vary from molecule to molecule, this emphasis on price and value rather than scientific breakthrough exemplifies a new definition of innovation in the biopharma sector.